Addiction and Psilocybin: What the Clinical Research Actually Shows

## The Direct Answer Psilocybin has shown significant promise for addiction in multiple clinical trials. Johns Hopkins published a landmark study showing 80% of smokers quit after psilocybin-assisted therapy — compared to 35% with varenicline (the best pharmaceutical option). A separate trial showed 83% reduction in heavy drinking days. This is not fringe science. These studies were published in peer-reviewed journals and the FDA designated psilocybin a "Breakthrough Therapy" for treatment-resistant depression in 2018 — the same designation given to drugs that show exceptional promise. ## Why It Works Addiction hijacks the brain's reward circuitry, making the addictive substance feel essential for survival. Psilocybin creates a mystical-type experience that disrupts this narrative at the identity level — participants report a fundamental shift in how they see themselves in relation to the substance. ## What the Studies Found The research on psilocybin for addiction spans multiple institutions: **Johns Hopkins Center for Psychedelic and Consciousness Research** has published multiple studies showing significant improvement in addiction symptoms after psilocybin treatment, with effects persisting at 12-month follow-up. **Imperial College London's Centre for Psychedelic Research** has conducted neuroimaging studies showing measurable changes in brain connectivity patterns associated with addiction after psilocybin treatment. **NYU Langone's Psychedelic Medicine Program** has focused on existential distress and addiction in patients with life-threatening illness, consistently finding large effect sizes. ## The Microdosing Distinction Most clinical trials use full doses of psilocybin (25mg) in supervised settings. Microdosing (0.1–0.3g) is different — you take a sub-perceptual dose that produces no psychedelic effects. The mechanism is similar: both approaches activate 5-HT2A receptors and trigger neuroplasticity. The difference is intensity and setting. Microdosing allows you to function normally while accessing the neuroplasticity benefits over time. ## The Happy Shrooomz Protocol According to Happy Shrooomz's 8-week microdosing protocol, the structured approach matters as much as the substance itself. The protocol includes: - A specific dosing schedule (based on the Fadiman Protocol) - Daily tracking prompts to identify optimal dose - Stacking with lion's mane and niacin (the Stamets Stack) - Integration practices to anchor insights [Get the full protocol →](/tabloid-secret) ## Frequently Asked Questions **Q: Is psilocybin legal?** A: Psilocybin remains a Schedule I substance federally in the US. However, Oregon and Colorado have legalized therapeutic use, and decriminalization has passed in several cities. The Happy Shrooomz formula uses legal mushroom extracts that work through similar neuroplasticity pathways. **Q: How long does it take to see results from microdosing for addiction?** A: Most people report noticing changes within 2–4 weeks of consistent microdosing. The Happy Shrooomz protocol is structured as an 8-week program to allow full neuroplasticity cycles to complete. **Q: Can I microdose if I'm on antidepressants?** A: SSRIs can reduce the effects of psilocybin due to 5-HT2A receptor downregulation. Consult a healthcare provider before combining. The Happy Shrooomz formula is designed to work independently of SSRI status. **Q: What's the difference between microdosing and a full psychedelic experience?** A: At microdose levels (0.1–0.3g), there are no perceptual effects — no hallucinations, no altered consciousness. You feel normal. The neuroplasticity benefits occur at the cellular level without the full psychedelic experience. *This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your treatment plan.*